{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:10:06Z","timestamp":1780445406869,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"DOI":"10.7759\/cureus.43138","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T13:16:37Z","timestamp":1691500597000},"source":"Crossref","is-referenced-by-count":2,"title":["FIP1L1-PDGFRA Clonal Hypereosinophilic Syndrome With Eosinophilic Myocarditis and Intracardiac Thrombus"],"prefix":"10.7759","author":[{"given":"Margaret","family":"Locke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex K","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent P","year":"2012","unstructured":"Valent P, Klion AD, Horny HP, et al.. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012, 130:607-612.e9. 10.1016\/j.jaci.2012.02.019","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali W","year":"2022","unstructured":"Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:129-48. 10.1002\/ajh.26352","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2007.07.004","article-title":"Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders","volume":"27","author":"Ackerman SJ","year":"2007","unstructured":"Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007, 27:357-75. 10.1016\/j.iac.2007.07.004","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane MM","year":"2010","unstructured":"Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010, 126:179-81. 10.1016\/j.jaci.2010.03.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317202","article-title":"Hypereosinophilic syndrome: considerations for the cardiologist","volume":"108","author":"Bondue A","year":"2022","unstructured":"Bondue A, Carpentier C, Roufosse F. Hypereosinophilic syndrome: considerations for the cardiologist. Heart. 2022, 108:164-71. 10.1136\/heartjnl-2020-317202","journal-title":"Heart"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu SQ","year":"2016","unstructured":"Qu SQ, Qin TJ, Xu ZF, et al.. Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016, 7:33229-36. 10.18632\/oncotarget.8906","journal-title":"Oncotarget"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand F","year":"2013","unstructured":"Legrand F, Renneville A, MacIntyre E, et al.. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases. Medicine (Baltimore). 2013, 92:e1-9. 10.1097\/MD.0b013e3182a71eba","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.903323","article-title":"Case report: multimodal imaging guides the management of an eosinophilic leukemia patient with eosinophilic myocarditis and intracardiac thrombus","volume":"9","author":"Si J","year":"2022","unstructured":"Si J, Zhang X, Chen N, et al.. Case report: multimodal imaging guides the management of an eosinophilic leukemia patient with eosinophilic myocarditis and intracardiac thrombus. Front Cardiovasc Med. 2022, 9:903323. 10.3389\/fcvm.2022.903323","journal-title":"Front Cardiovasc Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65128-4","article-title":"Hypereosinophilia with concurrent venous thromboembolism: clinical features, potential risk factors, and short-term outcomes in a Chinese cohort","volume":"10","author":"Liu Y","year":"2020","unstructured":"Liu Y, Meng X, Feng J, Zhou X, Zhu H. Hypereosinophilia with concurrent venous thromboembolism: clinical features, potential risk factors, and short-term outcomes in a Chinese cohort. Sci Rep. 2020, 10:8359. 10.1038\/s41598-020-65128-4","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85852-9","article-title":"Venous thrombosis and predictors of relapse in eosinophil-related diseases","volume":"11","author":"R\u00e9au V","year":"2021","unstructured":"R\u00e9au V, Vall\u00e9e A, Terrier B, et al.. Venous thrombosis and predictors of relapse in eosinophil-related diseases. Sci Rep. 2021, 11:6388. 10.1038\/s41598-021-85852-9","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1018394","article-title":"Case report: application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus","volume":"13","author":"Zou M","year":"2022","unstructured":"Zou M, Liu G, Li Y. Case report: application of non-VKA oral anticoagulants in patient of idiopathic hypereosinophilic syndrome with intracardiac thrombus. Front Pharmacol. 2022, 13:1018394. 10.3389\/fphar.2022.1018394","journal-title":"Front Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/173236-fip1l1-pdgfra-clonal-hypereosinophilic-syndrome-with-eosinophilic-myocarditis-and-intracardiac-thrombus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:33Z","timestamp":1707508893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/173236-fip1l1-pdgfra-clonal-hypereosinophilic-syndrome-with-eosinophilic-myocarditis-and-intracardiac-thrombus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.43138","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}